Competitive PositioningAnalyst maintains an Underperform rating with a $14 price objective, indicating concerns about PHVS's competitive positioning in the HAE market.
Market CompetitionEkterly, recently approved as the first oral on-demand HAE therapy, will have at least 12 months of market exclusivity before PHVS can enter the market.
Market Entry TimingThe company is likely to enter the market at least 12 months after a competitor, potentially affecting its market share capture.